Pancreatic Cancer Research

ResearcherFourth Affiliated Hospital of China Medical UniversityActive in the last 2 years

Jia Ma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3127-3824; OpenAlex author ID A5100689223. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2023: 2 papers · 2024: 2 papers

Papers 4

  1. PELI1 overexpression contributes to pancreatic cancer progression through upregulating ubiquitination-mediated INPP5J degradation. Last author DOI 10.1016/j.cellsig.2024.111194↗
  2. HTF4 modulates the transcription of GID2 to promote the malignant biological behavior of pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.08.008↗
  3. GID2 Interacts With CDKN3 and Regulates Pancreatic Cancer Growth and Apoptosis. First author DOI 10.1016/j.labinv.2023.100122↗
  4. PSMD12 interacts with CDKN3 and facilitates pancreatic cancer progression. Co-author DOI 10.1038/s41417-023-00609-y↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenyang Zhou · 4 shared papers, 2023–2024 · strength 0.97
  2. Xiangpeng Meng · 4 shared papers, 2023–2024 · strength 0.97
  3. Xin Deng · 3 shared papers, 2023–2024 · strength 0.73
  4. Baosheng Wang · 2 shared papers, 2023 · strength 0.46
  5. Baosheng Wang · 1 shared paper, 2024 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.